Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

NCT07147348 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07147348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07147348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 27, 2025
Completion date
August 31, 2028
Enrollment
375 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor